Reduced Reactivity Towards Anti-Protamine Antibodies of a Low Molecular Weight Protamine Analogue

By Tsui B.   Singh V.K.   Liang J.F.   Yang V.C.  

Thrombosis Research, Vol. 101, Iss. 5, 2001-03 ,pp. : 417-420

Elsevier

Access to resources Recommend Favorite

Hemostasis and thrombosis: basic principles and clinical practice, 4th edition

By Heptinstall Stan  

Platelets, Vol. 12, Iss. 5, 2001-08 ,pp. : 319-319

Informa Healthcare

Access to resources Recommend Favorite

The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.

By Holst J.   Lindblad B.   Bergqvist D.   Hedner U.   Nordfang O.   Ostergaard P.  

Thrombosis Research, Vol. 86, Iss. 4, 1997-05 ,pp. : 343-348

Elsevier

Access to resources Recommend Favorite

A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents

By Mahan Charles  

Journal of Thrombosis and Thrombolysis, Vol. 37, Iss. 3, 2014-04 ,pp. : 271-278

Springer Publishing Company

Access to resources Recommend Favorite

Clinical Experiences with Low-Molecular Weight Heparins in Pediatric Patients

By Hofmann S.   Knoefler R.   Lorenz N.   Siegert G.   Wendisch J.   Mueller D.   Taut-Sack H.   Dinger J.   Kabus M.  

Thrombosis Research, Vol. 103, Iss. 5, 2001-09 ,pp. : 345-353

Elsevier

Access to resources Recommend Favorite